Theranos Names Former Abbott Diagnostics Executive Cass Grandone as Head of Product Development

PALO ALTO, Calif.--()--Theranos today announced that a key role has been filled on the company’s executive team, with the arrival of Cass Grandone as Senior Vice President of Product Development. Mr. Grandone’s career has included R&D roles of increasing responsibility, including leading the delivery of Abbott’s multi-billion dollar ARCHITECT and Accelerator diagnostic platforms.

“Cass brings a passion for healthcare along with considerable experience in launching global diagnostic platforms that save and improve lives”

“Cass brings a passion for healthcare along with considerable experience in launching global diagnostic platforms that save and improve lives,” said Theranos CEO Elizabeth Holmes. “His leadership will be critical to helping Theranos realize its longstanding mission to make lab testing more accessible.”

“I was drawn to Theranos by the unique potential of the miniLab to provide comprehensive lab services during a single patient visit,” said Mr. Grandone. “Now that I am here, I look forward to helping Theranos deliver on its promise as a pioneer in the diagnostics industry.”

Mr. Grandone began at Abbott Diagnostics in design and systems engineering, eventually becoming Divisional Vice President of Core Lab Assays & Systems Product Development and leading Abbott’s next generation “ci” Core Lab and “s” Transfusion AlinityTM platforms. He has deep experience bringing products through FDA approval and, while at Abbott, implemented company-wide modernization of R&D portfolio governance, design control frameworks and statistical support automation. Most recently, Mr. Grandone was Vice President Global Infusion Systems R&D at Hospira, a Pfizer company. He holds a BS in Mechanical Engineering from the University of Illinois-Champaign/Urbana.

ABOUT THERANOS

Founded in 2003 by Elizabeth Holmes, Theranos, Inc. is a health technology company headquartered in Palo Alto, Calif. Its proprietary miniLab platform is designed to enable earlier disease detection and intervention by facilitating small-sample collection, testing and rapid communication of diagnostic information in distributed settings. To learn more about Theranos, visit www.theranos.com.

Contacts

Theranos, Inc.
Tali Mackay, 650-546-2321

Recent Stories

  • Theranos Reaches Settlement with Walgreens
    August 01, 2017
    PALO ALTO, Calif.--(EON: Enhanced Online News)--Theranos, Inc. announced today that it has entered a confidential settlement agreement with Walgreen Co. and Walgreens Boots Alliance, Inc., resolvin... more »
  • Theranos Finalizes Shareholder Recapitalization
    May 16, 2017
    PALO ALTO, Calif.--(EON: Enhanced Online News)--Theranos, Inc. announced today the successful closing of an exchange offer designed to recapitalize its most recent investors. Holders of more than 9... more »
  • Theranos Reaches Settlement with Partner Fund Management
    May 01, 2017
    PALO ALTO, Calif.--(EON: Enhanced Online News)--Theranos, Inc. announced today that it has resolved two lawsuits brought against it by Partner Fund Management LP (PFM), a San Francisco-based hedge ... more »
RSS feed for Theranos, Inc.